Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

Por Kongnakorn, Thitima, Sterchele, James A, Salvador, Christopher G, Getsios, Denis, Mwamburi, Mkaya
Publicado em 2014

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

Por Dorian, Paul, Kongnakorn, Thitima, Phatak, Hemant, Rublee, Dale A., Kuznik, Andreas, Lanitis, Tereza, Liu, Larry Z., Iloeje, Uchenna, Hernandez, Luis, Lip, Gregory Y.H.
Publicado em 2014